MARKET

BVAXF

BVAXF

Biovaxys Technol
OTCMQB

Real-time Quotes | Nasdaq Last Sale

0.071
-0.012
-14.77%
Closed 16:00 06/24 EDT
OPEN
0.071
PREV CLOSE
0.083
HIGH
0.071
LOW
0.071
VOLUME
1.50K
TURNOVER
107
52 WEEK HIGH
0.504
52 WEEK LOW
0.069
MARKET CAP
6.55M
P/E (TTM)
-1.2886
1D
5D
1M
3M
1Y
5Y
Clinical Study Collaborator HCL Sends First Surgically Excised Ovarian Cancer Tumors to BioVaxys for BVX-0918 Vaccine Process Development
BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company"), announced today that its clinical study collaborator Hospices Civils de Lyon in France ("HCL") has surgically excised the first ovarian cancer tumors from cancer pat...
CNW Group · 06/15 12:00
Bio-Manufacturing Partner BioElpida Completes Next Phase of BVX-0918 GMP Production for EU Clinical Study
BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company"), announced today that its Lyon, France-based bioproduction partner, BioElpida ("BioElpida"), has completed the creation of multiple OVCAR-3 cell banks as the next ste...
CNW Group · 06/08 12:00
BioVaxys and The Ohio State University Progress Pan-Sarbecovirus Vaccine Research Program
BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company") announced today that The Ohio State University ("Ohio State"), its research collaborator that is jointly evaluating the Company's novel approach for a "universal vacc...
CNW Group · 06/03 12:00
BioVaxys Confirms First Clinical Site and Principal Investigators for Ovarian Cancer Vaccine Trial and Enters into Second Tumor Cell Supply Agreement
BioVaxys Technology Corp. (CSE: BIOV; FRA: 5LB; OTCQB: BVAXF) ("BioVaxys" or "Company"), announced today that Hospices Civils de Lyon, France ("HCL") has agreed to serve as a clinical study site for the Phase I study of BVX-0918, the Company's autologous h...
PR Newswire · 05/18 12:00
BRIEF-Biovaxys Technology Corp - International Patent Application Filed For Cervical Cancer Vaccine
reuters.com · 05/02 13:36
International Patent Application Filed for Cervical Cancer Vaccine
BioVaxys Technology Corp. (CSE: BIOV), (FRA:5LB), (OTCQB:BVAXF) ("BioVaxys" or "Company"), announced today that it has continued to expand the patent coverage for its cancer vaccine platform by filing an international patent application through the Patent ...
CNW Group · 05/02 12:00
BRIEF-BioVaxys Reports Appointment To Board Of Directors
reuters.com · 04/29 12:44
BIOVAXYS ANNOUNCES APPOINTMENT TO BOARD OF DIRECTORS
BioVaxys Technology Corp. (CSE: BIOV, FRA: 5LB, OTCQB: BVAXF) ("BioVaxys" or the "Company") is pleased to announce that Mr. Anthony Dutton has been appointed as a director of the Company.
CNW Group · 04/29 12:32
More
No Data
Learn about the latest financial forecast of BVAXF. Analyze the recent business situations of Biovaxys Technol through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
No Data
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.67%
Pharmaceuticals & Medical Research
+2.48%
Key Executives
President/Founder/Chief Operating Officer
Kenneth Kovan
Chief Executive Officer/Founder/Director
James Passin
Founder
David Berd
Chief Financial Officer/Secretary
Lachlan Mcleod
Director
Anthony Dutton
Director
David Wang
Independent Director
Daren Hermiston
No Data
No Data
About BVAXF
Biovaxys Technology Corp., formerly Lions Bay Mining Corp., is a Canada-based clinical-stage immunotherapeutics company. The Company develops vaccine platforms for SARS-CoV-2 and various cancers.

Webull offers kinds of Biovaxys Technology Corp stock information, including OTCMQB:BVAXF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BVAXF stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BVAXF stock methods without spending real money on the virtual paper trading platform.